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Background: To evaluate if human papillomavirus (HPV) self-sampling (Self-HPV) using a dry vaginal swab is a valid
alternative for HPV testing.
Methods: Women attending colposcopy clinic were recruited to collect two consecutive Self-HPV samples: a Self-
HPV using a dry swab (S-DRY) and a Self-HPV using a standard wet transport medium (S-WET). These samples were
analyzed for HPV using real time PCR (Roche Cobas). Participants were randomized to determine the order of the
tests. Questionnaires assessing preferences and acceptability for both tests were conducted. Subsequently, women
were invited for colposcopic examination; a physician collected a cervical sample (physician-sampling) with a
broom-type device and placed it into a liquid-based cytology medium. Specimens were then processed for the
production of cytology slides and a Hybrid Capture HPV DNA test (Qiagen) was performed from the residual liquid.
Biopsies were performed if indicated. Unweighted kappa statistics (к) and McNemar tests were used to measure the
agreement among the sampling methods.
Results: A total of 120 women were randomized. Overall HPV prevalence was 68.7% (95% Confidence Interval (CI)
59.3–77.2) by S-WET, 54.4% (95% CI 44.8–63.9) by S-DRY and 53.8% (95% CI 43.8–63.7) by HC. Among paired
samples (S-WET and S-DRY), the overall agreement was good (85.7%; 95% CI 77.8–91.6) and the κ was substantial
(0.70; 95% CI 0.57-0.70). The proportion of positive type-specific HPV agreement was also good (77.3%; 95% CI 68.2-
84.9). No differences in sensitivity for cervical intraepithelial neoplasia grade one (CIN1) or worse between the two
Self-HPV tests were observed. Women reported the two Self-HPV tests as highly acceptable.
Conclusion: Self-HPV using dry swab transfer does not appear to compromise specimen integrity. Further study in
a large screening population is needed.
Trial registration: ClinicalTrials.gov: NCT01316120
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Cervical cancer incidence and mortality have decreased
considerably since the introduction of cervical cancer
screening programs in Western countries. However,
despite these advances in secondary prevention, there
are 500,000 new cases every year worldwide, mostly
(85%) in developing countries [1-3]. Cervical cancer is* Correspondence: sarah.untiet@hcuge.ch
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reproduction in any medium, provided the orpredominantly a disease of low-resource countries be-
cause of limited access to healthcare and lack of cervical
cancer screening programs [4]. Current data indicate
that testing for high-risk human papillomavirus (HPV)
types could be used as a primary screening method, and
allowing women to do the sampling by themselves (Self-
HPV) has been shown to have results similar to those
obtained by health care professionals [5-8]. In countries
with an existing cervical cancer screening program,
Self-HPV is regarded as a possible alternative for women
who decline to participate in the existing screeningLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ited or no screening resources, due to the prohibitively
high cost of cytology-based screening and lack of qualified
health care professionals. Self-HPV has the potential to
overcome some of these barriers [4-11]. Available data
regarding Self-HPV studies have been generated from
samples collected with standard “wet” transport media like
phosphate-buffered saline (PBS) or other transport media
developed more recently. PBS is inexpensive but requires
refrigeration, while newer transport media can be stored
at room temperature but are costlier.
Acceptability studies for Self-HPV indicate that the
method is generally well accepted by women, but revealed
that some of women have doubts about the validity of the
method. One of these was the concern about manipulating
the test tube and spilling out the transport medium during
the sampling procedure, which some patients interpreted
as incorrect and feared that it might affect the test result
[12,13]. This is an important issue, because it might lead
to lower acceptability and participation rates in screening
programs using Self-HPV. Finally, for low resource set-
tings, a standard transport medium may be impractical
and unavailable, because of the cost. Dry vaginal swabs
may be more convenient and less expensive. Small studies
suggest that HPV tests sampled by physicians using dry
vaginal swabs are as accurate as those performed with
standard transport medium for HPV detection [12,14,15].
The feasibility of Self-HPV with dry swabs transported
and stored at room temperature might facilitate screening
strategies in low-resource settings. To address this ques-
tion, the aim of our study was to assess the performance
of Self-HPV using dry swabs (S-DRY) compared with
Self-HPV using wet transport medium (S-WET). We
also explored the acceptability of the two Self-HPV
methods.
Methods
This study was conducted by the Geneva University
Hospitals, Switzerland. The Ethics Committee of the
Geneva University Hospitals, Switzerland, approved the
study (number of approval: CE 10–184 MAT-PED 10–
044). A signed informed consent form (ICF) was required
for enrollment of participants in the study. This trial was
registered at ClinicalTrials.gov (Identifier: NCT01316120).
Patients
A total of 120 women were prospectively enrolled from
our colposcopy clinic between November 2010 and
August 2011. We randomized the sequence of the two
HPV tests to avoid any potential biases that may advan-
tage the first test. We included women aged 20 years or
older, who understood the study procedures and accepted
to participate by signing the ICF. Exclusion criteria were
pregnancy and previous conization or hysterectomy.Procedures
The participants were randomized and received oral
instructions by a physician or a research nurse about
how to perform the Self-HPV, a self-collected vaginal
sample. In brief, they were instructed to wash their
hands before performing the procedure, to insert the
swab into the vagina and to rotate it three times in both
directions. The women were handed two self-sampling
kits (S-DRY: a Dacron swab with a plastic bag; S-WET: a
flocked swab with a tube filled with 1 ml of liquid trans-
port medium (ESwab®, Copan, Brescia, Italy)) and were
directed to a private, well-lit room to perform both
samplings. Subsequently the participants were asked to
complete a questionnaire on demographic characteristics,
knowledge about HPV and preference between the two
Self-HPV methods. The questionnaire used a 4-point scale
to measure the degree of acceptability, physical discomfort
and pain felt using the Self-HPV as well as the preference
between the two Self-HPV methods. Participants then
underwent a colposcopic examination. During this pro-
cedure, a cervical sample for liquid-based cytology and
Hybrid Capture (HC) HPV test(QIAGEN AG Garstligweg
8 CH-8634 Hombrechtikon, Switzerland) was obtained
using a broom type cervical brush and rinsing it in
Preservcyt™ buffer solution (Hologic, Inc Bedford,
Massachusetts, U.S.). A biopsy for histological analysis
was performed if necessary.
Self samples were stored at room temperature and the
time between sample collection and analysis ranged
between 5 to 15 days.
HPV testing
Real time PCR
Material from dry swabs (S-Dry samples) was placed into
1 ml of sterile phosphate-buffered saline (PBS)and the
tubes were vortexed for 3×15 sec. Then, 0.5 ml of each
sample was used for nucleic acid extraction and the rest
was frozen at −20°C for storage. Tubes containing S-Wet
samples (1 ml) were also vortexed for 3×15 sec and then,
0.5 ml of each sample was used for nucleic acid extraction
and the rest of sample was frozen at −20°C for storage.
HPV extraction, detection and genotyping were carried
out from S-Dry and S-Wet specimens using the Cobas
4800 (Roche Diagnostics International Ltd Forrenstrasse 2
CH-6343 Rotkreuz, Switzerland) HPV test according to
the manufacturer’s recommendations. This assay is an
automated DNA extraction, PCR amplification and
real-time detection of 14 High Risk HPV (HR-HPV)
genotypes. It uses the beta-globin gene as an internal
extraction and amplification control. PCR amplification
and detection are performed in a single tube, where
probes with four different reporter dyes track the differ-
ent targets in the multiplex reaction: (i) HPV 16, and 18
individually, (ii) 12 HR-HPV types (i.e., HPV 31, -33, -35,
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and (iii) beta-globin.
Hybrid Capture (HC2)
Postcytology vials processed on the ThinPrep 2000 System
((Hologic,Inc Bedford, Massachusetts, U.S.) were used. At
least 4 mL of remaining PreservCyt™ solution was used for
the Hybrid Capture HPV DNA test. Samples were
processed in the sample conversion kit and tested with
HC2 according to the manufacturer's protocol with probe
B for HR genotypes (a pool of full length HPV RNA
probes against 13 HR-HPV genotypes including types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). Sample
reactivity was measured in relative light units (RLU). A
specimen was considered positive for HR HPV DNA if
the ratio of the specimen RLU to the mean RLU of trip-
licates of a positive control at 1 pg per ml was >3.00.
Samples with ratios between 1.00 and 3.00 were retested
twice and were considered positive if 2 out of 3 results
had a ratio >1.00.
Both methods used in this study, (HC and real time
PCR) are FDA approved diagnostic methods. Because
HC is considered as the reference standard to analyze
physician-sampled specimen, as any methods in consid-
eration to replace it should be as accurate as this
method of screening.
Statistical analysis
The sample size necessary to validate a difference in test
performance of 10% or more was calculated assuming a
HPV prevalence of at least 40%. The proportion of posi-
tive agreement (PPA) between paired S-WET and S-DRY
samples was calculated by dividing the number of samples
testing positive for HPV in both tests by the number of
samples testing positive in either S-WET or S-DRY.
Cohens Kappa was calculated to measure the inter-test
agreement between the self-sampling methods inFigure 1 Agreement of type-specific HPV detection between S-WET, S
sampling; S-WET = vaginal swabs with wet transport medium used for self
or mixed infections; **HPV 18 in single or mixed infections; ***One or moreterms of HPV risk categories. Positive agreement be-
tween S-WET and S-DRY was calculated as described
by Wolfrum et al. [16].
Results
One hundred twenty women were included in the study,
of whom we excluded four for not having paired samples,
three for inconclusive HPV test results (all three were
S-WET samples) and one who refused further participa-
tion after performing Self-HPV. For the study analysis
we included 112 women with 224 paired samples and
completed questionnaires. The median age of partici-
pants was 31 years (range 21–63 years).
The HPV prevalence was 68.7% (95% Confidence
Interval (CI) 59.3–77.2) detected by S-WET, 54.4% (95% CI
44.8–63.9) by S-DRY and 53.8% (95% CI 43.8–63.7) by
HC. Mono-infections with HPV 16 or 18 were identified
in 19.4% of participants, and combined infections with
HPV 16 or 18 and other high-risk types were identified in
36.3%. Infection with one or more HPV types other than
HPV 16 or 18 was observed in 44.1% of participants. HPV
16 was detected in 49.3% of cases and HPV 18 in 9%.
The overall test agreement between S-WET and S-DRY
was 85.7% (95% CI 77.8–91.6), with a 79.2% positive
agreement. Cohen’s kappa for inter-test agreement was
0.70 (95% CI 0.53-0.88). Positive agreement for type
specific HPV was 77.3% (95% CI 68.2–84.9). The inter-test
agreement was good between S-WET and S-DRY for
type-specific detection of HPV 16 and non-16/18 HPV
types as well as for all HPV positive cases. The inter-test
agreements between HC and S-DRY and between HC
and S-WET were inferior to the inter-test agreement of
S-WET and S-DRY (Figure 1, Table 1).
Cytological diagnosis was available for 111 cases. For the
comparison of S-WET and S-DRY with HC we excluded
seven cases that were missing HC results. Histological
diagnosis was performed in 73 cases, in the other cases-DRY and HC. Note: S-DRY = dry vaginal swabs used for self-
- sampling; HC = Hybrid Capture physician sampeld; *HPV 16 in single
of the non-16/18 high risk HPV types, in single or mixed infections.
Table 1 Pooled data on women testing positive for HPV with S-WET, S-DRY and HC (Physician-sampling) by the grade
of cytology (N=104) and histopathology (N=73)
Grade of cytology Total (N) S-WET % (95% CI) S-DRY % (95% CI) HC % (95% CI)
NILM 27 55.6 (35.3-74.5) 33.3 (16.5-54.0) 40.7 (22.4-61.2)
ASC-US* 35 60.0 (42.1-76.1) 48.6 (31.2-66.1) 48.6 (31.2-66.1)
LSIL 33 78.8 (61.1-91.0) 69.7 (51.3-84.4) 63.6 (45.1-79.6)
HSIL 9 100 (66.4-100) 88.9 (51.8-99.7) 66.7 (29.9-92.5)
Grade of histology
Normal 28 53.8 (33.9-72.5) 39.3 (21.5-59.4) 28.6 (13.2-48.7)
CIN 1 22 72.7 (49.8-89.3) 68.2 (45.1-86.1) 72.7 (49.8-89.3)
CIN 2+ 23 91.3 (72.0-98.9) 73.9 (51.6-89.8) 69.6 (47.1-86.8)
Note: S-DRY dry vaginal swabs used for self-sampling, S-WET vaginal swabs with wet transport medium used for self-sampling, HC Hybrid Capture, NILM Negative
for intraepithelial lesion or malignancy: ASC-US Atypical squamous cells of undetermined significance, ASC-H Atypical squamous cells-cannot rule out high grade,
AGC Atypical glandular cells, LSIL Low-grade squamous intraepithelial lesion, HSIL High-grade squamous intraepithelial lesion, CIN Cervical intraepithelial neoplasia;
*ASC-US summarizes ASC-US, ASC-H, AGC.
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(Table 2).
In cases of abnormal cytology, the discordance of HPV
results was at a consistent level of about 10% for all
stages of severity. The discordance was elevated at 22.5%
in cases of normal cytology. HPV positivity increased
with increasing severity of cytological diagnosis, and
reached 100% in HSIL (using S-WET). No difference in
sensitivity or specificity was found between S-WET and
S-DRY.
In the case of CIN 1 or higher lesions, the stratified
overall test agreement was 88.6% (κ=0.70). S-DRY
detected HPV in 73.9% of cases of CIN2/3, while S-WET
was positive in 91.3% and HC was positive in 69.6%. The
agreement between S-WET and S-DRY was highest in
CIN1. The performance of both self-tests was comparable
to HC samples taken by a physician.
We did not observe any statistically significant differ-
ence between S-DRY and HC or between S-WET and HC
(Table 2).
One hundred and twelve questionnaires were com-
pleted, and no difference in acceptability between the
two Self-HPV tests was observed. Most women (96.4%)
were favorable to the idea of performing self-sampling atTable 2 Comparison of S-WET and S-DRY in identifying variou
HPV detected Number of samples
WET+ DRY+ WET+ DRY-
Subject level comparison
Any HPV 61 16
HPV 16 and/or HPV 18 32 13
Other HR-HPV 47 12
Note: HPV prevalence analyzed on subject level: subjects infected with HR-HPV/ spe
HR-HPV types.
*The observed proportion positive agreement=2a/(N+(a2d)), where a=the number o
number of samples that were negative for HPV in both the wet and dry samples an
S-DRY dry vaginal swabs used for self-sampling, S-WET vaginal swabs with wet tranhome, while three women (2.7%) were opposed to this
idea and one did not answer the question. Fifty women
experienced Self-HPV as slightly to severely painful or
embarrassing, but no preference could be highlighted
between the two Self-HPV tests. Some of the women
(15/112 for S-WET; 6/112 for S-DRY) evaluated one of
the self-tests as more complex than the other, while the
majority did not report any difference in complexity.
Twenty-seven women had higher confidence in S-WET,
while two had higher confidence in S-DRY, but the large
majority (83/112) thought both self-tests were equally
reliable.
Discussion
In recent years, we have learned that, with appropriate
instruction, self-sampling of HPV specimens yield simi-
lar results compared with those collected by health care
professionals. The high percentage of agreement for
high-risk HPV between these two approaches suggests
that Self-HPV is a promising alternative to physician-
sampling for HPV testing and cervical cancer screening
[17]. Belinson et al. reported that self-collected vaginal
specimens showed lower sensitivity and lower specificity
than physician collected endocervical specimen analyzeds HPV genotypes
Positive agreement*




cific HR-HPV types compared with those not infected with HR-HPV/ specific
f samples that were positive for HPV in both the wet and dry samples, d=the
d N=all samples tested for HPV.
sport medium used for self-sampling.
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using more sensitive PCR-based assays could improve
the sensitivity to a comparable level [18,19].
Recent studies reported that Self-HPV testing is more
sensitive than the Pap test in detecting CIN2+ in
Chineese and Mexican women of low socioeconomic
status [8,20]. Furthermore, a review by Gravitt, et al. in-
cludes the performance of self- vs clinician collected
swabs for detection of CIN2+ which provides a better
assessment of alternatives to physician sampling for
cervical cancer screening [21].
The possibility of using Self-HPV stored at ambient
temperature without transport media would clearly en-
hance and simplify the utility of Self-HPV. This could
reduce the costs of the methods, which might be attract-
ive for low-resource countries. Moreover, it may reduce
women’s concerns that the test quality is reduced by
accidentally spilling out some of the transport medium
[12,13]. We found that swabs transported in a dry state
were as accurate as those obtained with swabs shipped
in a wet transport medium, in terms of quality of results.
Of note, all dry samples were sufficient for analysis while
three of the wet samples were insufficient. The test
performance between S-WET and S-DRY methods was
similar according to the overlap of the 95% confidence
intervals. Cohen’s kappa calculated for the inter-test
agreement (0.7) corresponds to a substantial agreement
and is in line with the results of other studies addressing
this question in the context of physician-sampling
[14,15,22]. Shah et al. compared vaginal swabs performed
by physicians, with and without transport medium, and
established kappa values ranging between 0.69 and 0.81
[15]. Likewise, similar to our results, the concordance of
the S-DRY and S-WET results was higher compared with
the concordance of any Self-HPV, wet or dry, with the
physician-sampled specimen [15]. If S-WET is used as a
screening method, women should be reassured about the
good test performance to ensure trust in the screening
results.
In this study we used different swabs for S-WET and
S-DRY. The S-WET swab was a flocked swab that con-
sists of fine and short filaments fixed at the top of the
stick while the swab used the S-DRY swab was a stand-
ard Dacron swab consisting of a long filament enrolled
around a stick. Krech et al. compared flocked and rayon
swabs for their sensitivity to detect HPV infection and
noticed that the sensitivity of flocked swabs was higher
[12]. They explained this observation with a higher
capacity of adhesion in the flocked swabs, which leads to
a better proportion of DNA detection [12]. This devices
difference might explain the trend of our results in favor
of S-WET. However, the use of different swabs did not
cause significant differences in test performance, which
might even give room to the question if a simple Dacronswab used without transport medium might be an
acceptable alternative.
A shortcoming of our study is the use of different
HPV DNA detection assays for self-collected vaginal
specimens and physician-collected endocervical speci-
mens. The number of variables that differ in addition to
wet vs. dry transport weakens our conclusion about the
feasibility of dry transportation. Other weaknesses of our
study are the small sample size and the fact that our
population was recruited in a colposcopic clinic having a
high rate of HPV prevalence. Even though the HPV posi-
tivity in S-WET compared with S-DRY is not statistically
significant, it seems to point in the direction of S-DRY be-
ing slightly less sensitive than S-WET. Additional work is
needed to conduct a study in a real context of screening
with a larger sample size to determine if S-DRY and
S-WET have equal sensitivity.
Conclusions
Our study shows that Self-HPV swabs can be successfully
transported in a dry state at ambient temperature without
greatly altering specimen integrity. Self-sampling for HPV
testing using S-DRY could be an alternative to other self-
sampling methods that require “wet” transport media.
Advantages of the dry method include a simplification of
the method , as well as its ease of use and lower cost may
be of advantage for women with restricted access to health
care delivery. However, further research is needed to con-
firm the equality of both methods in a large screening
population.
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